Skip to content
Open access

Association of plasma biomarkers with longitudinal change in age- and Alzheimer’s disease-related brain atrophy patterns

Sep 2026 · medRxiv · 0 citations
Medicine

TL;DR

Among CU individuals, plasma p-tau217 was associated with subsequent MCI/dementia due to AD and showed the most extensive associations with longitudinal AD-related brain atrophy, compared with SPARE-BA or R-indices capturing subcortical, diffuse cortical, or perisylvian atrophy.

Abstract

INTRODUCTION: Determining whether plasma biomarkers are preferentially associated with Alzheimer's disease (AD)-related rather than age-related brain atrophy patterns may clarify their prognostic and diagnostic clinical use.

Methods

Using data from the Baltimore Longitudinal Study of Aging (N=818), we examined cross-sectional plasma A{beta}42/A{beta}40, GFAP, NfL, p-tau181, and p-tau217 measurements obtained while participants were cognitively unimpaired (CU). During follow-up, 104 participants developed mild cognitive impairment (MCI)/dementia (74 due to AD, 24 due to non-AD, 6 unknown etiology). 2,293 longitudinal brain MRIs were used to quantify multidimensional atrophy pattern scores reflecting brain age (SPARE-BA), AD-like patterns (SPARE-AD), and five dominant dimensions of atrophy (R-indices). We investigated the associations of plasma biomarkers and atrophy pattern scores at index visit with conversion to MCI/dementia due to AD. We then examined the associations of plasma biomarkers with longitudinal change in pattern scores using linear mixed effects models.

Results

p-tau181, A{beta}42/A{beta}40 (Lumipulse), and p-tau217 were associated with incident MCI/dementia due to AD but not non-AD etiologies, while GFAP was associated with incident MCI/dementia due to both AD and non-AD. All four biomarkers were associated with longitudinal SPARE-AD changes. A{beta}42/A{beta}40 (Quanterix and Lumipulse), p-tau181, and p-tau217 were associated with longitudinal parieto-temporal atrophy. p-tau217 was the only biomarker associated with longitudinal medial temporal lobe atrophy. We did not find associations between plasma biomarkers and SPARE-BA or R-indices capturing subcortical, diffuse cortical, or perisylvian atrophy.

Discussion

Among CU individuals, plasma p-tau217 was associated with subsequent MCI/dementia due to AD and showed the most extensive associations with longitudinal AD-related brain atrophy.

Read PDF

Similar papers

Open access Dec 2025

Developing Topics.

BACKGROUND Demonstrating the specificity of plasma biomarkers to AD-related neurodegeneration would add support to their prognostic and diagnostic clinical use. METHOD Participants from the Baltimore Longitudinal Study of Aging were cognitively unimpaired at the time of their plasma Aβ42/Aβ40, GFAP, NfL (Quanterix Ne...

Murat Bilgel, Ishaan Shah, Jasmine M. Cooper et al. · 0 citations
Open access Aug 2026

Association between Alzheimer’s disease-related genes and neurodegenerative blood-based biomarkers in Indian adults

Rare and common variants in AD- and neurodegenerative biomarker-associated genes with increased frequency in India compared to other populations may impact blood levels of neurodegenerative biomarkers in South Asians.

Hasan Abu-Amara, Wei Zhao, Zheng Li et al. · 0 citations
Open access Sep 2026

Health-related factors and their impact on blood-based biomarkers of Alzheimer's disease

In CSF-confirmed participants, age emerged as the most consistent predictor of plasma biomarker levels, particularly NFL and pTau181, which suggests that plasma biomarkers are influenced primarily by age and genetic background rather than by metabolic factors in this cohort.

Carolin I. Kurz, Marleen Taute, Paulina Tegethoff et al. · 0 citations
Open access Sep 2026

Spatiotemporal Atrophy Subtypes in Alzheimer's Disease: Neurodegenerative-Vascular Associations and Potential Prognostic Value.

Bomarker-confirmed AD comprised internally reproducible atrophy trajectories with distinct cognitive, vascular, and molecular profiles and may complement fluid biomarkers and conventional volumetry for patient stratification and prognosis.

Chen-Hui Mao, Yu-Yue Qiu, Bo Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.